Drugs / CD22 CAR T-cell
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06081478 | Jan 2022 → Dec 2025 overdue | B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04788472 | Mar 2021 → Aug 2024 | B-cell adult acute lymphocytic leukemia | Zhejiang University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD22-CAR-T cell | “The dosage for CD19-CAR-T cell was 2×10e6/kg and CD22-CAR-T cell was 1×10e6/kg.” NCT06081478 ↗1“Twenty-five patients (89.3%) received sequential CD22 CAR T-cell therapy” PMID 40244598 ↗ Jun 2025 |
| Modality | Cell therapy | “sequential CD19 and CD22 CAR T-cell therapies” PMID 40244598 ↗ Jun 2025 |
| Target | CD22 | “CAR-T cells targeting CD19 and CD22” NCT04788472 ↗ |